Published in Gastroenterology on November 26, 2009
Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. Mol Cell Proteomics (2010) 1.77
Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. Gastroenterology (2014) 1.61
Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology (2013) 1.47
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. Aliment Pharmacol Ther (2012) 1.47
HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol (2011) 1.37
Viral disruption of the blood-brain barrier. Trends Microbiol (2012) 1.14
Hepatocyte polarity. Compr Physiol (2013) 1.06
Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. J Virol (2012) 1.02
A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration. J Hepatol (2011) 1.00
Angiogenesis and liver fibrosis. World J Hepatol (2015) 0.93
Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication. Hepatology (2011) 0.89
The SR-BI partner PDZK1 facilitates hepatitis C virus entry. PLoS Pathog (2010) 0.89
Mechanism of hepatitis C virus (HCV)-induced osteopontin and its role in epithelial to mesenchymal transition of hepatocytes. J Biol Chem (2013) 0.89
Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells. J Virol (2013) 0.89
The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy. Proteomics Clin Appl (2014) 0.88
Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles. J Virol (2011) 0.88
Recent advances in hepatitis C virus cell entry. Viruses (2010) 0.87
Structural and functional hepatocyte polarity and liver disease. J Hepatol (2015) 0.84
In vitro systems for the study of hepatitis C virus infection. Int J Hepatol (2012) 0.82
Clathrin mediates infectious hepatitis C virus particle egress. J Virol (2015) 0.81
Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies. World J Hepatol (2012) 0.81
SHIP2 regulates epithelial cell polarity through its lipid product, which binds to Dlg1, a pathway subverted by hepatitis C virus core protein. Mol Biol Cell (2013) 0.81
New Methods in Tissue Engineering: Improved Models for Viral Infection. Annu Rev Virol (2014) 0.81
The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virus. PLoS One (2011) 0.80
Hypoxia-inducible factors as molecular targets for liver diseases. J Mol Med (Berl) (2016) 0.79
Viral Interactions with PDZ Domain-Containing Proteins-An Oncogenic Trait? Pathogens (2016) 0.78
Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry. World J Gastroenterol (2011) 0.78
HCV IRES-mediated core expression in zebrafish. PLoS One (2013) 0.78
The missing pieces of the HCV entry puzzle. Future Virol (2015) 0.76
Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
Autocrine VEGF signaling is required for vascular homeostasis. Cell (2007) 7.37
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science (2003) 4.56
Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol (2006) 3.84
Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem (1999) 3.47
Possible involvement of phosphorylation of occludin in tight junction formation. J Cell Biol (1997) 3.35
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology (2009) 3.07
Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A (2001) 3.06
Molecular pathogenesis of cholestasis. N Engl J Med (1998) 2.68
Vascular endothelial growth factor localization in the adult. Am J Pathol (2006) 2.20
Cytokine regulation of tight junctions. Biochim Biophys Acta (2008) 2.16
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res (2000) 2.07
Hypoxia inducible factor (HIF) function in innate immunity and infection. J Mol Med (Berl) (2007) 1.90
VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci (2006) 1.86
Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J Biol Chem (2009) 1.81
Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem (1998) 1.80
Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol (2004) 1.64
VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol (2001) 1.63
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Phosphorylation of Tyr-398 and Tyr-402 in occludin prevents its interaction with ZO-1 and destabilizes its assembly at the tight junctions. J Biol Chem (2008) 1.55
Early steps of the hepatitis C virus life cycle. Cell Microbiol (2007) 1.51
Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol (2009) 1.44
Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol (2005) 1.30
Hepatitis C virus proteins. World J Gastroenterol (2007) 1.28
Which in vitro models could be best used to study hepatocyte polarity? Biol Cell (2008) 1.26
Human hepatocyte culture. Methods Mol Biol (2006) 1.23
Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor. J Virol (2007) 1.19
Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. J Med Chem (2005) 1.14
Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology (2009) 1.07
Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology (2000) 1.06
Identification and analysis of occludin phosphosites: a combined mass spectrometry and bioinformatics approach. J Proteome Res (2009) 1.05
Hepatitis C virus core protein augments androgen receptor-mediated signaling. J Virol (2008) 0.98
Spontaneous clearance of hepatitis C virus infection post-liver transplantation is associated with rapidly changing quasispecies: a single case report. Liver Transpl (2000) 0.93
Hepatitis C virus entry: possible targets for therapy. Gut (2008) 0.92
Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol (2004) 0.91
Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl Surg (1998) 0.88
Leaky junctions and cholestasis: a tight correlation. Gastroenterology (1996) 0.85
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol (2006) 2.74
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Tumour vascular targeting. Nat Rev Cancer (2005) 2.56
Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res (2004) 2.52
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med (2011) 2.47
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol (2006) 2.45
Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology (2008) 2.43
Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension (2008) 2.42
Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation (2007) 2.35
Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia. Circulation (2013) 2.34
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS (2006) 2.23
Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics (2002) 2.21
Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res (2006) 2.12
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04
Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest (2005) 1.96
Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (2010) 1.92
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
Anticancer strategies involving the vasculature. Nat Rev Clin Oncol (2009) 1.82
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer (2012) 1.76
Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol (2004) 1.76
The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol (2008) 1.76
Superinfection exclusion in cells infected with hepatitis C virus. J Virol (2007) 1.71
Organellar dynamics during the cell cycle of Toxoplasma gondii. J Cell Sci (2008) 1.70
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res (2002) 1.68
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Golgi biogenesis in Toxoplasma gondii. Nature (2002) 1.67
Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis (2008) 1.64
Inferring viral quasispecies spectra from 454 pyrosequencing reads. BMC Bioinformatics (2011) 1.62
Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. FASEB J (2004) 1.62
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem (2002) 1.61
VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol (2007) 1.61
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Measuring tubulin content in Toxoplasma gondii: a comparison of laser-scanning confocal and wide-field fluorescence microscopy. Proc Natl Acad Sci U S A (2002) 1.55
Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res Clin Oncol (2005) 1.55
Development of the antibody response in acute HIV-1 infection. AIDS (2004) 1.54
Development of hepatitis C virus genotype 3a cell culture system. Hepatology (2014) 1.53
Bifunctional role for VEGF-induced heme oxygenase-1 in vivo: induction of angiogenesis and inhibition of leukocytic infiltration. Blood (2003) 1.49
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Carbon monoxide inhibits sprouting angiogenesis and vascular endothelial growth factor receptor-2 phosphorylation. Thromb Haemost (2014) 1.48
Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res (2006) 1.48
Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology (2013) 1.47
Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis. Crit Care Med (2015) 1.45
Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo. Development (2011) 1.44
Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol (2009) 1.44
EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J Biol Chem (2003) 1.44
Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41
Repulsive axon guidance molecule Slit3 is a novel angiogenic factor. Blood (2009) 1.37
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37